BrP-LPA
Product Sizes
1 mg
ECH-L-7416-1MG
5 mg
ECH-L-7416-5MG
About this Product
- SKU:
- ECH-L-7416
- Extra Details:
- BrP-LPA acts as both an Autotaxin inhibitor (94% inhibition at 10 uM) and pan LPA receptor antagonist (LPA1: 1.5 uM, LPA2: 1.4 uM, LPA3: 1.2 uM, LPA4: 0.27 uM). BrP-LPA inhibits the invasiveness of NIH3T3 ras ATX cells by 40% and decreases chemotaxis by 23%. BrP-LPA reduces the size of breast (MDA-MB-231), colon (HCT-116) and melanoma (B16F10) tumors in mouse models. It also attenuates collagen-induced arthritis PPARG Gamma is not activated by BrP-LPA. \n \n \n \nStorage \n-20 °C \nFeatured in Publications \n1) Jiang, G., Y. Xu, et al. (2007). "Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA." ChemMedChem 2(5): 679-90. \n2) Zhang, H., X. Xu, et al. (2009). "Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell Migration In vitro and Causes Tumor Regression In vivo." Cancer Res 69: 5441 \n3) Schleicher, S. M., D. K. Thotala, et al. (2011). "Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature." PLoS ONE 6(7): e22182. \n4) Nikitopoulou, I., E. Kaffe, et al. (2013). "A Metabolically-Stabilized Phosphonate Analog of Lysophosphatidic Acid Attenuates Collagen-Induced Arthritis." PLoS ONE 8(7): e70941 \n \n \n \nDocuments \nTechnical Data Sheet, Echelon
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- Please refer to datasheet
- Supplier:
- Echelon Biosciences
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Inhibitors
